Cargando…

Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity

Nasal drug delivery has become a popular research field in the last years. This is not surprising since the nose possesses unique anatomical and physical properties. Via the nasal mucosa local, systemic, and directly central nerve systemic (CNS) effect is achievable. Powders have favorable physicoch...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambrus, Rita, Gieszinger, Péter, Gáspár, Róbert, Sztojkov-Ivanov, Anita, Ducza, Eszter, Márki, Árpád, Janáky, Tamás, Tömösi, Ferenc, Kecskeméti, Gábor, Szabó-Révész, Piroska, Bartos, Csilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179229/
https://www.ncbi.nlm.nih.gov/pubmed/32120992
http://dx.doi.org/10.3390/molecules25051065
_version_ 1783525626525777920
author Ambrus, Rita
Gieszinger, Péter
Gáspár, Róbert
Sztojkov-Ivanov, Anita
Ducza, Eszter
Márki, Árpád
Janáky, Tamás
Tömösi, Ferenc
Kecskeméti, Gábor
Szabó-Révész, Piroska
Bartos, Csilla
author_facet Ambrus, Rita
Gieszinger, Péter
Gáspár, Róbert
Sztojkov-Ivanov, Anita
Ducza, Eszter
Márki, Árpád
Janáky, Tamás
Tömösi, Ferenc
Kecskeméti, Gábor
Szabó-Révész, Piroska
Bartos, Csilla
author_sort Ambrus, Rita
collection PubMed
description Nasal drug delivery has become a popular research field in the last years. This is not surprising since the nose possesses unique anatomical and physical properties. Via the nasal mucosa local, systemic, and directly central nerve systemic (CNS) effect is achievable. Powders have favorable physicochemical properties over liquid formulations. Lamotrigine (LAM) is an antiepileptic agent with a relatively mild side effect spectrum, but only available in tablet form on market. Reducing the particle size to the nano range can affect the bioavailability of pharmaceutical products. The aim of this article was to continue the work started, compare the in vitro properties of a nanonized lamotrigine containing nasal powder (nanoLAMpowder) and its physical mixture (PM) that were prepared by dry milling. Moreover, to study their trans-epithelial absorption to reach the blood and target the brain by axonal transport. Due to the dry milling technique, the particle size of LAM, their surface and also their structure changed that led to higher in vitro dissolution and permeability rate. The results of the in vivo tests showed that the axonal transport of the drug was assumable by both intranasal formulations because the drug was present in the brain within a really short time, but the LAM from the nanoLAMpowder liberated even faster.
format Online
Article
Text
id pubmed-7179229
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71792292020-04-28 Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity Ambrus, Rita Gieszinger, Péter Gáspár, Róbert Sztojkov-Ivanov, Anita Ducza, Eszter Márki, Árpád Janáky, Tamás Tömösi, Ferenc Kecskeméti, Gábor Szabó-Révész, Piroska Bartos, Csilla Molecules Article Nasal drug delivery has become a popular research field in the last years. This is not surprising since the nose possesses unique anatomical and physical properties. Via the nasal mucosa local, systemic, and directly central nerve systemic (CNS) effect is achievable. Powders have favorable physicochemical properties over liquid formulations. Lamotrigine (LAM) is an antiepileptic agent with a relatively mild side effect spectrum, but only available in tablet form on market. Reducing the particle size to the nano range can affect the bioavailability of pharmaceutical products. The aim of this article was to continue the work started, compare the in vitro properties of a nanonized lamotrigine containing nasal powder (nanoLAMpowder) and its physical mixture (PM) that were prepared by dry milling. Moreover, to study their trans-epithelial absorption to reach the blood and target the brain by axonal transport. Due to the dry milling technique, the particle size of LAM, their surface and also their structure changed that led to higher in vitro dissolution and permeability rate. The results of the in vivo tests showed that the axonal transport of the drug was assumable by both intranasal formulations because the drug was present in the brain within a really short time, but the LAM from the nanoLAMpowder liberated even faster. MDPI 2020-02-27 /pmc/articles/PMC7179229/ /pubmed/32120992 http://dx.doi.org/10.3390/molecules25051065 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ambrus, Rita
Gieszinger, Péter
Gáspár, Róbert
Sztojkov-Ivanov, Anita
Ducza, Eszter
Márki, Árpád
Janáky, Tamás
Tömösi, Ferenc
Kecskeméti, Gábor
Szabó-Révész, Piroska
Bartos, Csilla
Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity
title Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity
title_full Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity
title_fullStr Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity
title_full_unstemmed Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity
title_short Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity
title_sort investigation of the absorption of nanosized lamotrigine containing nasal powder via the nasal cavity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179229/
https://www.ncbi.nlm.nih.gov/pubmed/32120992
http://dx.doi.org/10.3390/molecules25051065
work_keys_str_mv AT ambrusrita investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT gieszingerpeter investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT gasparrobert investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT sztojkovivanovanita investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT duczaeszter investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT markiarpad investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT janakytamas investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT tomosiferenc investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT kecskemetigabor investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT szaboreveszpiroska investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity
AT bartoscsilla investigationoftheabsorptionofnanosizedlamotriginecontainingnasalpowderviathenasalcavity